Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: Efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily

Giuseppe Saglio, Andreas Hochhaus, Yeow Tee Goh, Tamas Masszi, Ricardo Pasquini, Frederic Maloisel, Philipp Erben, Jorge Cortes, Ronald Paquette, M. Brigid Bradley-Garelik, Chao Zhu, Herve Dombret

Research output: Contribution to journal › Article › peer-review

107 Scopus citations

Fingerprint

Dive into the research topics of 'Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: Efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily'. Together they form a unique fingerprint.

Medicine & Life Sciences